CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for VioQuest Pharmaceuticals, Inc . is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

VioQuest Pharmaceuticals, Inc .
180 Mount Airy Rd Ste 102
Phone: (732) 274-0399p:732 274-0399 BASKING RIDGE, NJ  07920-2064  United States Ticker: VOQP VOQP
Business Summary
VioQuest Pharmaceuticals, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of clinical stage drug therapies targeting both the molecular basis of cancer and side effects of cancer treatment. The Company’s lead compound under development is Xyfid (1% topical uracil) for the treatment and prevention of Hand-Foot Syndrome (HFS). In parallel, Xyfid is also being developed to treat dry skin conditions and manage the burning and itching associated with various diseases of the skin or dermatoses. In addition, VioQuest Pharmaceuticals is developing VQD-002 (triciribine phosphate monohydrate or TCN-P), a small molecule anticancer compound that inhibits activation of protein kinase B (PKB or AKT), a key component of a signaling pathway known to promote cancer cell growth and survival, as well as resistance to chemotherapy and radiotherapy. On July 16, 2007, the Company completed the sale of Chiral Quest, Inc. to Chiral Quest Acquisition Corp.
(Source: 10KSB)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/200812/31/2007YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Financial Officer, Vice President Christopher P.Schnittker 47 7/18/2008 7/18/2008
Vice President - Research & Development VernonAlvarez 4/14/2008 4/14/2008
Director Johnson Y.Lau 61 11/1/2005 11/1/2005
Director Wayne W.Mills 51 2/9/2010 2/9/2010

Subsidiaries
Business Name Address City State/Province Country
Chiral Quest Inc 7 Deer Park Drive Monmouth Junction NJ United States

Business Names
Business Name
Chiral Quest (Jiashan) Ltd.
Chiral Quest, Inc.
Greenwich Therapeutics, Inc.
5 additional Business Names available in full report.

General Information
Number of Employees: 3 (As of 6/30/2008)
Outstanding Shares: 5,461,644 (As of 8/18/2008)
Shareholders: 1,790
Stock Exchange: OTC
Federal Tax Id: 581486040
Fax Number: (302) 655-5049


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, August 28, 2023